The FDA is requiring Eli Lilly to conduct extensive postmarketing studies for its newly approved GLP-1 pill Foundayo (orforglipron) to further assess potential safety risks.
The agency said additional data is needed to evaluate risks, including major adverse cardiovascular events, drug-induced liver injury and medullary thyroid cancer, as well as delayed gastric emptying associated with the therapy, according to an April 1 letter.
The approval includes multiple required studies and registries, including long-term monitoring of thyroid cancer risk for at least 15 years and a 10-year pediatric registry assessing growth, development and adverse events in patients treated for obesity.
Lilly must also complete pediatric trials, including a 72-week study in patients ages 12-17 and an 84-week study in patients ages 6-11, along with additional studies tracking pregnancy exposure and long-term outcomes.
The FDA approved Foundayo for adults with obesity or overweight with weight-related conditions based on data submitted Jan. 20, but said ongoing studies are needed to better define the drug’s long-term safety profile.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
